Plain-English translation of NCT06227026 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing , a newer type of cancer treatment that uses your own immune cells to fight certain blood cancers. Researchers take your T cells (a type of white blood cell), reprogram them in the laboratory to recognize and attack cancer cells, and then put them back into your body. This approach is being studied for patients whose cancer has come back or stopped responding to previous treatments.
Many patients with blood cancers like lymphoma and leukemia have limited options once their cancer returns or stops responding to standard therapy. This medication represents a potentially powerful alternative by harnessing the body's own immune system to target and destroy cancer cells in a more precise way.
You likely qualify if…
You likely don't qualify if…
You would first receive chemotherapy to prepare your body for the new immune cells. Then your own T cells would be collected and sent to a laboratory where researchers reprogram them over several weeks. Once the treatment is ready, you would receive the reprogrammed cells back through an infusion. You would then need frequent hospital visits and blood tests to monitor how well the treatment is working and watch for any side effects. This is a pilot study, so the research team will be closely monitoring a small group of patients (up to 10 people total).
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States